新的研究显示 天线Dx的SKY92测试 更能辨别出高风险多位骨髓瘤患者 New study shows SkylineDx's SKY92 test better identifies high-risk multiple myeloma patients.

在美国血液学会会议上提出的一项新研究表明,SkylineDx的SKY92测试可以帮助比传统方法更准确地识别高风险多发性骨髓瘤患者. A new study presented at the American Society of Hematology conference shows that SkylineDx's SKY92 test can help identify high-risk multiple myeloma patients more accurately than traditional methods. 研究在九个美国癌症中心进行, 发现高风险SKY92生物标记的病人存活率更低, 帮助医生调整更好的治疗方法。 Conducted across nine U.S. cancer centers, the research found that patients with high-risk SKY92 biomarkers had worse survival rates, aiding doctors in tailoring better treatments. 个人化医学的这一进展可以改善多位间皮瘤患者的治疗结果。 This advancement in personalized medicine could improve outcomes for multiple myeloma patients.